Alise Reicin, M.D.
Alise Reicin, MD, was most recently, President, Global Clinical Development, for Celgene where she oversaw the development and approval of drugs across their pipeline in Oncology, Hematology and Autoimmune diseases and Fibrosis. She currently serves on the board of directors of Homology Medicines, a gene therapy company. Dr. Reicin has extensive early and late clinical development experience working across a broad range of therapeutic areas, including playing a leadership role which contributed to the approval of 8 novel medicines. Dr. Reicin previously served as Head of Global Clinical Development, for EMD Serono. Prior to this, Dr. Reicin served as Vice President, Oncology at Merck. In this capacity, she led Merck’s Keytruda (anti-PD-1) program and oversaw the initial development and filing activities worldwide for melanoma and non small cell lung cancer, and the initiation of development plans in 7 additional indications including breast cancer. Prior to Merck, Dr. Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital. She has a B.S. in biochemistry from Barnard College of Columbia University and received her MD from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT. Her prior board work includes serving as a founding member of the JCC of the Upper West Side, a member of Barnard’s Scientific Advisory Committee and a member of the NJ chapter of the Arthritis Foundation. She is married to Robert Boiarsky and is the mother of 3 sons and 2 daughters in law.